

Munich Cancer Registry



- ▶ Incidence and Mortality
- ▶ Selection Matrix
- ▶ Homepage
- ▶ *Deutsch*

Mammarian Paget disease

Survival

Year of diagnosis	1988-1997	1998-2016
Patients	31	236
Diseases	31	236
Cases evaluated	28	203
Creation date	08/22/2018	
Export date	08/09/2018	
Population (females)	2.43 m	



Munich Cancer Registry
Cancer Registry Bavaria - Upper Bavaria Regional Center
at Klinikum Grosshadern/IBE
Marchioninstr. 15
Munich, 81377
Germany

<https://www.tumorregister-muenchen.de/en>

https://www.tumorregister-muenchen.de/en/facts/surv/sMPDf_E-Mammarian-Paget-disease-survival.pdf

Index of figures and tables

Fig./Tbl.		Page
1a	Relative survival by period of diagnosis (chart)	3
1b	Survival by period of diagnosis (table)	3
2a	Survival of total cohort (chart)	4
2b	Survival of total cohort (table)	4
3a	Observed survival by age category (chart)	5
3b	Relative survival by age category (chart)	5
3c	Survival by age category (table)	6
4a	Observed survival by histology (chart)	7
4b	Relative survival by histology (chart)	7
4c	Survival by histology (table)	8
5a	Time to first progression (chart)	9
5b	Time to first progression (table)	9




Figure 1a. Relative survival of patients with mammarian Paget disease by period of diagnosis. Included in the evaluation are 216 cases diagnosed between 1988 and 2016.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

Years	Period of diagnosis					
	1988-1997 n=28		1998-2006 n=86		2007+ n=102	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0
1	100.0	101.3	97.7	99.9	93.4	96.9
2	96.3	102.5	90.6	94.4	93.4	98.7
3	88.9	95.4	83.5	87.9	91.9	99.1
4	81.5	89.9	74.1	80.0	88.1	98.1
5	77.8	86.8	71.7	79.3	85.9	99.5
6			70.5	79.3	85.9	101.1
7			68.1	78.6		
8			65.6	77.0		
9			63.0	76.3		
10			60.2	74.7		
11			58.7	73.5		
12			55.0	70.8		

Table 1b. Observed (obs.) and relative (rel.) survival of patients with mammarian Paget disease by period of diagnosis for period 1988-2016 (N=216).




Figure 2a. Observed, expected and relative survival of the total cohort with mammalian Paget disease. Included in the evaluation are 188 cases diagnosed between 1998 and 2016.

Years	Group	
	obs. %	rel. %
0	100.0	100.0
1	95.5	98.4
2	91.7	96.8
3	87.0	93.5
4	79.6	87.9
5	77.3	87.8
6	76.4	88.8
7	72.9	87.0
8	70.8	86.0
9	68.4	85.5
10	65.4	83.7
11	63.7	82.3
12	59.6	79.3

Table 2b. Observed (obs.) and relative (rel.) survival of the total cohort with mammalian Paget disease for period 1998-2016 (N=188).




Figure 3a. Observed survival of patients with mammarian Paget disease by age category. Included in the evaluation are 216 cases diagnosed between 1988 and 2016.




Figure 3b. Relative survival of patients with mammarian Paget disease by age category. Included in the evaluation are 216 cases diagnosed between 1988 and 2016.

Years	Age category			
	0-59 yrs n=82		60+ yrs n=134	
	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	100.0	99.6	93.6	98.2
2	97.2	97.8	89.2	97.4
3	94.2	93.8	82.8	93.5
4	89.6	89.8	73.7	87.1
5	86.5	86.6	71.4	89.1
6	83.3	83.7	69.0	90.2
7	81.7	83.4	62.5	85.9
8	81.7	83.2	58.0	83.0
9	81.7	83.1	54.8	83.1
10	81.7	82.9	48.6	78.9

Table 3c. Observed (obs.) and relative (rel.) survival of patients with mammalian Paget disease by age category for period 1988-2016 (N=216).




Figure 4a. Observed survival of patients with mammarian Paget disease by histology. For 188 of 188 cases diagnosed between 1998 and 2016 valid data could be obtained for this item.




Figure 4b. Relative survival of patients with mammarian Paget disease by histology. For 188 of 188 cases diagnosed between 1998 and 2016 valid data could be obtained for this item.

Histology						
Years	Paget disease n=23		Paget disease + DCIS n=116		Paget disease + IDC n=49	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0
1			97.2	100.0	89.4	92.8
2			95.2	100.2	79.6	84.6
3			92.1	98.5	71.6	75.7
4			87.5	96.2		
5			86.2	97.6		
6			86.2	99.3		
7			83.5	99.3		
8			80.3	97.9		
9			78.5	97.3		
10			73.9	94.4		
11			73.9	93.7		

Table 4c. Observed (obs.) and relative (rel.) survival of patients with mammarian Paget disease by histology for period 1998-2016 (N=188).




Figure 5a. Time to first progression of 179 patients with mammalian Paget disease diagnosed between 1998 and 2016 (in solid cancers M0 only) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

Years	Type of progression						
	Any type (CI)	Any type (1-KM)	Local relapse (CI)	Local relapse (1-KM)	Lymph node (CI)	Lymph node (1-KM)	Distant metastasis (CI)
	n=179 %	n=179 %	n=179 %	n=179 %	n=179 %	n=179 %	n=179 %
0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
1	3.0	3.0	0.6	0.6	0.6	0.6	1.2
2	5.6	5.7	2.5	2.6	0.6	0.6	2.5
3	9.9	10.3	4.7	5.0	1.3	1.4	5.4
4	10.7	11.2	4.7	5.0	1.3	1.4	5.4
5	11.6	12.2	5.6	6.0	1.3	1.4	5.4
6	12.5	13.2	5.6	6.0	1.3	1.4	6.3
7	13.4	14.3	5.6	6.0	1.3	1.4	7.2
8	13.4	14.3	5.6	6.0	1.3	1.4	7.2
9	14.9	16.2	5.6	6.0	1.3	1.4	8.6
10	16.5	18.4	5.6	6.0	1.3	1.4	8.6
11	16.5	18.4	5.6	6.0	1.3	1.4	8.6
12	16.5	18.4	5.6	6.0	1.3	1.4	8.6

<i>cont'd</i>	Type of progression		
	Distant metast. (1-KM)	NOS (CI)	NOS (1-KM)
	n=179 %	n=179 %	n=179 %
Years			
0	0.0	0.0	0.0
1	1.3	0.6	0.6
2	2.6	1.2	1.3
3	5.6	2.6	2.8
4	5.6	3.4	3.8
5	5.6	3.4	3.8
6	6.7	3.4	3.8
7	7.8	3.4	3.8
8	7.8	3.4	3.8
9	9.6	3.4	3.8
10	9.6	5.1	6.2
11	9.6	5.1	6.2
12	9.6	5.1	6.2

Table 5b. Time to first progression of patients with mammarian Paget disease for period 1998-2016 (N=179).

Shortcuts

MCR Munich Cancer Registry, Germany

NCI National Cancer Institute, USA

SEER Surveillance, Epidemiology, and End Results, USA

UICC Union for International Cancer Control, Geneva

DCO Death certificate only Death certificate provides the only notification to the registry.

NA Not available

NOS Not otherwise specified

OS Overall/Observed survival Overall/Observed survival (Kaplan-Meier estimate)
Date of entry: diagnosis
Event: death from any cause

RS Relative survival Survival compared to “general population”,
ratio of observed to expected survival (Ederer II method),
reflecting cancer specific survival

AS Assembled survival Assembled chart of
observed, expected, relative survival

CS Conditional survival Survival probability under the condition of surviving
a given period of time

TTP Time to progression Time to first progression / relapse
Date of entry: diagnosis
Event: (progression / relapse): first local-, lymph node recurrence,
distant metastasis or unspecified progression

1-KM 1 minus Kaplan-Meier estimator
 (“inverse” Kaplan-Meier estimator)

CI Cumulative incidence
Death as competing risk (according to Kalbfleisch und Prentice)

PPS Post-progression survival Survival since first progression / relapse (Kaplan-Meier estimate)
Date of entry (progression / relapse): first local-, lymph node
recurrence, distant metastasis or unspecified progression
Event: death from any cause

Recommended Citation

Munich Cancer Registry. Survival Mammarian Paget disease [Internet]. 2018 [updated 2018 Aug 22; cited 2018 Oct 1]. Available from: https://www.tumorregister-muenchen.de/en/facts/surv/sMPDf_E-Mammarian-Paget-disease-survival.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.